Government  Health IT
TwitterFacebookLinkedIn
  • Home
  • Topics
    • Cloud Computing
    • Election 2012
    • Electronic Health Record
    • ePrescribing
    • Health Information Exchange (HIE)
    • Meaningful Use
    • Medicaid
    • Medicare
    • Military Health
    • Mobile/ Wireless
    • NHIN
    • Policy & Legislation
    • Population Health
    • Privacy and Security
    • Quality and Safety
    • Telehealth
    • Workforce Management
  • Issues
    • Sept/Oct 2011
    • July/August 2011
    • May/June 2011
    • March/April 2011
    • Jan/Feb 2011
    • Nov/Dec 2010
  • Webinars
    • Upcoming Webinars
    • On Demand Webinars
  • White Papers
  • Blog
  • Events
  • Jobs
  • RSS
  • Slideshows
  • Videos
  • Podcasts
  • Newsletters
  • Advertise
  • LOGIN
  • REGISTER
  • SUBSCRIBE
Home ยป Press Releases

  • del.icio.us
  • Digg
  • Facebook
  • Google
  • Reddit
  • StumbleUpon
  • RSS Icon
  

New FDA statin labeling rules ignore hundreds of side effects, reports Natural Society

March 02, 2012 | Industry News Release
Source: Natural Society

PHILADELPHIA – Are statin drugs leading to more problems than just diabetes and memory loss as the FDA says? Following on the heels of the FDA announcing changes to the safety information on statin labels (e.g. Pfizer Inc's Lipitor, AstraZeneca's Crestor and Merck & Co's Zocor) concerning blood sugar and memory problems, a collection of consumer health groups, such as Natural Society, are raising public awareness about the hundreds of additional adverse health effects associated with their use as indicated by the published research from the National Library of Medicine.

A growing body of clinical research now indicates that this cholesterol-lowering class of drugs is associated with an alarming number of serious medical conditions -- research boldly flying in the face of national health policy, medical insurance premium guidelines, statin drug manufacturer advertising claims, and the general sentiment of the public, with approximately 1 in every 4 adult Americans over 45 currently using these drugs to "prevent heart disease."

Fundamentally, the research indicates that statin drugs damage the muscles and nerves in the body. There are well over 100 studies demonstrating the myotoxic, or muscle-harming effects of these drugs, and over 80 demonstrating the nerve-damaging effects. Since the heart is such a vital muscle innervated by a complex network of nerves, many healthcare providers now seriously question whether the unintended, unwanted side effects of statins are worse than the purported "cardiovascular" benefits they provide. Therefore, these peer reviewed research studies may also explain why rates of heart failure may be increasing in the general population who are given these drugs.

While the discovery that statin drugs, instead of preventing heart disease likely contributes to it, might be surprising; it should not distract from the more disturbing discovery that they contribute to over 300 disease and/or adverse health effects. Fortunately research has found that many of the statin-linked diseases, like diabetes, can be combated with natural substances like vitamin D.

In light of these findings many health professionals are now asking: Are those who are party to the manufacture, promotion, administration and/or prescribing of this chemical class of drugs, in violation of the medical ethical principle of informed consent?

 

Related Topics:
  • Philadelphia
  • AstraZeneca
  • Merck & Co
  • Pfizer Inc
  • National Library of Medicine
  • chemical
  • healthcare
  • Crestor
  • FDA
  • Lipitor
  • Vitamin D
  • Zocor

Reader Comments (0)Login to Post a Comment

Most Popular

Latest Headlines
Most Popular
  • Commentary: How data sharing between AHLTA and VistA is possible
  • Why modernizing state IT infrastructures is crucial for HIX
  • Report: HIT market will swell to $56B by 2017
  • OIG lets state Medicaid fraud units use federal funds for analytics
  • ONC launches cancer care app challenge
  • GetWellNetwork Growth Surges as Patient Engagement Takes Its Place as a Strategic Pillar of Accountable Care
  • Novitas Solutions starts Medicare JH contract work - jobs coming soon
  • Department of Defense and Department of Veterans Affairs Interagency Program Office Awards iEHR System Integration Contract to Systems Made Simple
  • VA awards contract to provide SoundCure Serenade to treat tinnitus
  • SAIC Awarded Contract by Defense Health Services System
more Press Releases

WEBINARS AND WHITE PAPERS

  • WHITE PAPERS
    Enterprise-class API Patterns for Cloud & Mobile
  • WHITE PAPERS
    Your Cloud in Healthcare - How to Use the Cloud to Achieve Greater Business Agility
  • WHITE PAPERS
    A Reference Architecture for Healthcare Benefit Exchange
  • WHITE PAPERS
    When Evolution Drives Revolution: The Cloud as a Business Model
  • WHITE PAPERS
    The First Federal Private Cloud: Learn to Shape, Transform & Manage Applications
More Resources
Syndicate content

HIMSS JOBMINE

  • Director of Clinical Applications - MidMichigan Health - Midland, MI
  • Information Services Director - Central Peninsula Hospital - Soldotna, AK
  • Director, Marketing and Business Development - Vermont Information Technology Leaders, Inc. - Burlington, VT
  • CIO - Bend Memorial Clinic - Bend, Oregon
  • Director of Clinical Transformation - Agnesian Healthcare - Fond du Lac, WI
more jobs
receive news by email

Marketplace

  • Home
  • Resource Central
  • Blog
  • Events
  • Jobs
  • Mobile Site
  • Advertise
  • RSS
  • About
  • Site map
  • Privacy Policy
Follow Government Health IT on TwitterLike Government Health IT on FacebookJoin Government Health IT on LinkedInRSS Subscriptions
BlogEvents
JobsMobile SiteMobile App
 
Healthcare IT NewsHealthcare Finance NewsHealthcare Payer NewsHIEWatch ICD10Watch mHIMSS PhysBizTech
©2013 MedTech Media Government Health IT is a publication of MedTech Media
Advertise About Us Privacy Policy